Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 30, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the registrant.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details a change in the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan ("the Plan").
- Date of Movement: November 23, 2005
- Previous Holding: 18,460,229 ADRs
- New Holding: 18,440,842 ADRs
- Average Price: $49.92
This change resulted from a movement in the fund. The Plan is a discretionary fund for employees and former employees. Directors Dr. J P Garnier and Dr. T Yamada are noted as potentially interested in the shares held in the fund in the same capacity as other employees.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly limited to the notification of the share transaction under Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the impact of the fund movement on the total share count held by the GlaxoSmithKline US Retirement Savings Plan.
- Confirm the potential interest of Directors Dr. J P Garnier and Dr. T Yamada in the fund's holdings.
- Note that this filing does not contain financial performance data for the period.